Free Trial
OTCMKTS:MITPF

Mithra Pharmaceuticals (MITPF) Stock Price, News & Analysis

→ $5,000 Gold? (From Stansberry Research) (Ad)
Free MITPF Stock Alerts
$6.75
0.00 (0.00%)
(As of 05/12/2023)
Compare
Today's Range
$6.75
▼
$6.75
50-Day Range
$6.75
▼
$6.75
52-Week Range
$6.75
▼
$7.75
Volume
N/A
Average Volume
1,600 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisHeadlinesShort Interest
MITPF stock logo

About Mithra Pharmaceuticals Stock (OTCMKTS:MITPF)

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

MITPF Stock Price History

MITPF Stock News Headlines

April 29, 2024 | finance.yahoo.com
Mithra updates on offers received in the context of its monetization process and on its Annual Report 2023
April 22, 2024 | finance.yahoo.com
Mithra secures court protection measures to advance monetization process
May 2, 2024 | Stansberry Research (Ad)
Gold Mania
Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).
April 17, 2024 | morningstar.com
Mithra Pharmaceuticals SA MITRAb
March 8, 2024 | finance.yahoo.com
Mithra reports full year 2023 financial results
March 5, 2024 | finanznachrichten.de
Mithra Pharmaceuticals: Mithra announces changes to its executive management
March 5, 2024 | finanznachrichten.de
Mithra Pharmaceuticals: Mithra initiates monetization process, receives bridge loan from existing lenders
March 5, 2024 | finance.yahoo.com
Mithra announces changes to its executive management
May 2, 2024 | Stansberry Research (Ad)
Gold Mania
Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).
March 5, 2024 | finance.yahoo.com
Mithra initiates monetization process, receives bridge loan from existing lenders
March 5, 2024 | finance.yahoo.com
Mithra announces changes to its executive management
February 29, 2024 | finance.yahoo.com
DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase
February 6, 2024 | finanznachrichten.de
Mithra Pharmaceuticals: Mithra updates on cash position
February 6, 2024 | finance.yahoo.com
Mithra updates on cash position
January 19, 2024 | barrons.com
Mithra Pharmaceuticals S.A.
January 17, 2024 | morningstar.com
Mithra Pharmaceuticals SA MITRA
December 21, 2023 | finance.yahoo.com
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel
December 20, 2023 | finanznachrichten.de
Mithra Pharmaceuticals: Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
December 20, 2023 | finance.yahoo.com
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
December 18, 2023 | markets.businessinsider.com
Mithra Reports Positive Review From DSMB On European Phase 3 Program For DONESTA
December 18, 2023 | finance.yahoo.com
Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial
December 4, 2023 | markets.businessinsider.com
Mithra: Gedeon Richter To Have Commercial Rights For ESTELLE, DONESTA In China
December 4, 2023 | finance.yahoo.com
Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China
November 30, 2023 | finance.yahoo.com
Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States
November 28, 2023 | finance.yahoo.com
Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam
November 7, 2023 | finance.yahoo.com
Mithra’s NEXTSTELLIS® granted additional patent in the United States
November 6, 2023 | finance.yahoo.com
Mithra releases invitation to its extraordinary securities holders’ meeting
See More Headlines
Receive MITPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mithra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
OTCMKTS:MITPF
CUSIP
N/A
CIK
N/A
Web
www.mithra.com
Phone
32 4 349 28 22
Fax
N/A
Employees
270
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Christophe Marechal
    Co-CEO & CFO
  • Mr. Xavier Paoli M.Sc.
    COO & Co-CEO
  • Dr. Graham K. Dixon Ph.D. (Age 63)
    Chief Scientific Officer
  • Mr. Alex Sokolowski
    Head of Investor Relations
  • Fanny Rozenberg
    Secretary of the Board & General Counsel
  • Fanny Storms
    Compliance Officer
  • Mr. Frederique Depraetere
    Communication Director
  • Ms. Catherine Lejeune
    HR Director
  • Mr. Jean-Manuel Fontaine
    Chief Commercial & External Affairs Officer
  • Prof. Jean-Michel Foidart M.D.
    Ph.D., President of the Scientific Advisory Board & Executive Director

Key Competitors

View All Competitors

MITPF Stock Analysis - Frequently Asked Questions

How have MITPF shares performed in 2024?

Mithra Pharmaceuticals' stock was trading at $6.75 at the beginning of 2024. Since then, MITPF stock has increased by 0.0% and is now trading at $6.75.
View the best growth stocks for 2024 here.

How do I buy shares of Mithra Pharmaceuticals?

Shares of MITPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MITPF) was last updated on 5/2/2024 by MarketBeat.com Staff

From Our Partners
Urgent Nvidia Warning
Altimetry
A.I. is a Tidal Wave - Here’s What to Buy
Chaikin Analytics
Truth about Trump you’ve never heard
Porter & Company
He Is Giving Away Bitcoin
Crypto Swap Profits
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
AI “wealth window” is closing June 25th
Paradigm Press
4 Cryptos BETTER than Bitcoin
True Market Insiders